On Monday, Prelude Therapeutics Inc (NASDAQ: PRLD) opened higher 11.96% from the last session, before settling in for the closing price of $0.80. Price fluctuations for PRLD have ranged from $0.80 to $6.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 12.13% at the time writing. With a float of $21.88 million, this company’s outstanding shares have now reached $42.18 million.
Let’s look at the performance matrix of the company that is accounted for 128 employees. In terms of profitability, gross margin is 81.18%, operating margin of -2230.11%, and the pretax margin is -2047.28%.
Prelude Therapeutics Inc (PRLD) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Prelude Therapeutics Inc is 60.25%, while institutional ownership is 35.27%.
Prelude Therapeutics Inc (PRLD) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.10% during the next five years compared to -43.14% drop over the previous five years of trading.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Check out the current performance indicators for Prelude Therapeutics Inc (PRLD). In the past quarter, the stock posted a quick ratio of 7.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (NASDAQ: PRLD) saw its 5-day average volume 0.8 million, a positive change from its year-to-date volume of 0.19 million. As of the previous 9 days, the stock’s Stochastic %D was 18.27%. Additionally, its Average True Range was 0.10.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 1.65%, which indicates a significant decrease from 29.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.75% in the past 14 days, which was lower than the 131.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3064, while its 200-day Moving Average is $3.5601. Nevertheless, the first resistance level for the watch stands at $0.9464 in the near term. At $0.9971, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.0720. If the price goes on to break the first support level at $0.8208, it is likely to go to the next support level at $0.7459. The third support level lies at $0.6952 if the price breaches the second support level.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
There are currently 55,035K shares outstanding in the company with a market cap of 49.29 million. Presently, the company’s annual sales total 0 K according to its annual income of -121,830 K. Last quarter, the company’s sales amounted to 3,000 K and its income totaled -32,270 K.
